Literature DB >> 8743532

Aging abolishes the renal response to L-arginine infusion in essential hypertension.

C Campo1, V Lahera, R Garcia-Robles, V Cachofeiro, J M Alcazar, A Andres, J L Rodicio, L M Ruilope.   

Abstract

A defect in the endothelium-dependent vasorelaxation could contribute to the development of arterial hypertension through the facilitation of renal vasoconstriction and sodium retention. In this study, we tested the hypothesis that aging impairs kidney function in essential hypertension through a derangement of nitric oxide-dependent renal mechanisms. To this end, we compared the renal response to an intravenous infusion of the precursor of nitric oxide synthesis, L-arginine, in young and aged essential hypertensives. In young hypertensives, L-arginine induced a significant increase in renal plasma flow, glomerular filtration rate, natriuresis and kaliuresis, without changes in filtration fraction. These effects were not observed in aged hypertensives. Neither PRA nor PA were affected by L-arginine infusion in any group. These results indicate that aging produces a derangement of endothelial function in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8743532

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  3 in total

1.  Augmentation of ferulic acid-induced vasorelaxation with aging and its structure importance in thoracic aorta of spontaneously hypertensive rats.

Authors:  Toshihiko Fukuda; Takahiro Kuroda; Miki Kono; Mai Hyoguchi; Mitsuru Tanaka; Toshiro Matsui
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-27       Impact factor: 3.000

2.  In vivo renal arginine release is impaired throughout development of chronic kidney disease.

Authors:  Gin-Fu Chen; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-11

Review 3.  The aging kidney: increased susceptibility to nephrotoxicity.

Authors:  Xinhui Wang; Joseph V Bonventre; Alan R Parrish
Journal:  Int J Mol Sci       Date:  2014-09-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.